Ernexa Therapeutics (ERNA) Institutional Ownership $1.66 +0.07 (+4.42%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Ernexa Therapeutics (NASDAQ:ERNA)CurrentInstitutional OwnershipPercentage70.55%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$1.04MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$953.88K Get ERNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Ernexa Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ERNA Institutional Buying and Selling by Quarter Ernexa Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025Corient Private Wealth LLC17,523$32K0.0%-93.3%0.228% 8/8/2025 Geode Capital Management LLC20,075$37K0.0%-93.2%0.273% 2/12/2025 Geode Capital Management LLC257,310$76K0.0%+1,159.2%4.756% 5/3/2024 Avidian Wealth Solutions LLC14,798$36K0.0%N/A0.274% 5/2/2024 Sippican Capital Advisors72,800$175K0.1%+34.7%1.346% 2/13/2024Lake Street Advisors Group LLC520,996$933K0.1%N/A9.630% 1/30/2024 Sippican Capital Advisors54,050$97K0.1%+92.3%0.999% 1/1/2024 Vanguard Group Inc.24,898$54K0.0%+30.6%0.460% 10/24/2023 Sippican Capital Advisors28,100$61K0.1%+30.1%0.519% 2/1/2023 Cypress Point Wealth Management LLC94,375$304K0.5%N/A3.210% 1/31/2023 Naviter Wealth LLC79,621$387K0.1%N/A2.708% (Data available from 1/1/2016 forward) ERNA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ERNA shares? During the previous two years, the following institutional investors and hedge funds held shares of Ernexa Therapeutics shares: Lake Street Advisors Group LLC ($933K), Sippican Capital Advisors ($175K), Vanguard Group Inc. ($54K), Geode Capital Management LLC ($37K), and Avidian Wealth Solutions LLC ($36K), Corient Private Wealth LLC ($32K).Learn more on Ernexa Therapeutics' institutional investors. What percentage of Ernexa Therapeutics' stock is owned by institutional investors? 70.55% of Ernexa Therapeutics' stock is owned by institutional investors. Learn more on ERNA's institutional investor holdings. Which institutional investors have been buying Ernexa Therapeutics' stock? The following institutional investors have purchased Ernexa Therapeutics' stock in the last 24 months: Lake Street Advisors Group LLC ($521.00K), Geode Capital Management LLC ($236.88K), Sippican Capital Advisors ($51.20K), Avidian Wealth Solutions LLC ($14.80K), and Vanguard Group Inc. ($5.83K). How much institutional buying is happening at Ernexa Therapeutics? Institutional investors have bought a total of 236,875 shares in the last 24 months. This purchase volume represents approximately $1.04M in transactions. Which of Ernexa Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Ernexa Therapeutics stock in the last 24 months: Geode Capital Management LLC ($273.07K), and Corient Private Wealth LLC ($245.34K). How much institutional selling is happening at Ernexa Therapeutics? Institutional investors have sold a total of 518,412 shares in the last 24 months. This volume of shares sold represents approximately $953.88K in transactions. Related Companies ATHE Major Shareholders ATNM Major Shareholders TELO Major Shareholders ADVM Major Shareholders LTRN Major Shareholders PRLD Major Shareholders ALGS Major Shareholders BRNS Major Shareholders SLGL Major Shareholders GANX Major Shareholders This page (NASDAQ:ERNA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access